Based on the first international conference in 2017. The second International Conference on Biomotors, Virus Assembly, and Nanobiotechnology Applications will be held next July in Columbus, Ohio. ExonanoRNA vigorously sponsors this conference to promote the growth of the field for RNA nanotechnology and its application in pharmaceutical reaserch.For more information, please see the website at http://rnanano.osu.edu/Guo/Biomotor2019/Biomotor2019.html
-Negative charge disallows nonspecific permeation of negatively charged cell membrane
-Controlled synthesis provides defined structure and stoichiometry
-Multi-valency allows combination therapy and simultaneous targeting and detection
-Targeted delivery allows receptor mediated endocytosis
-Advantageous size (10 – 40 nm)
-Extended in vivo half-life (5-12 hr compared to 15-45 min for siRNA)
-Avoidance of antibody induction (protein-free) allows repeated treatment for chronic diseases
- Favorable pharmacokinetic profile in mice:
Half-life (T1/2) : 5-10 hr compared to 0.25-0.76 hr of siRNA counterpart;
Clearance (Cl): <0.13 l/kg/hr,
Volume of distribution (V(d)): 1.2 l/kg;
Does not induce interferon (IFN) response or cytokine production；
Repeated IV administrations of up to 30 mg/kg do not result in toxicity.
- RNA nanoparticles are classified as chemical drugs rather than biologics. This classification facilitates drug approval.